SM-4300, a new intravenous immunoglobulin, showed 40% efficacy in treating severe bacterial infections in 13 patients, including those with leukemia and pneumonia. No adverse reactions were observed, suggesting its potential as an adjunctive therapy.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Context:
Purpose:
Summary:
Impact: